Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results
Date:5/7/2013

/span>, the Company's Chief Executive Officer, said, "Following the announcement of top-line data, we are now focusing our efforts and resources toward the pending NDA and MAA submissions.  We are also progressing with the U.S. Phase 2 CKD study, for which we expect to report top-line data in the third quarter of 2013."

The Company will host an investor conference call tomorrow, Wednesday, May 8, 2013, at 8:30am EDT, to discuss the Company's first quarter financial results and provide a business outlook for the remainder of 2013.In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.
ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of renal disease. Keryx is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Keryx has completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, conducted pursuant to a Special Protocol Assessment (SPA) agreement with the FDA, and the New Drug Application filing with the FDA and the Marketing Authorization Application filing with the EMA are pending submission.  Zerenex is also in Phase 2 development in the U.S. for the management of phosphorus and iron deficiency in anemic patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease.  In addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing approval of ferric citrate in
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
2. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results
4. Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference
5. Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
6. Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock
7. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Third Quarter 2012 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on Second Quarter 2012 Financial Results
9. Keryx Biopharmaceuticals Announces Upcoming Poster Presentation of Zerenex™ (ferric citrate) at the 49th ERA-EDTA Congress
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), a ... entered into an agreement with Merck KGaA, Darmstadt, ... in the United States and ... KGaA,s biopharmaceutical division on the development and commercialization of ... Ventana,s proprietary diagnostic assays. In alignment with Merck KGaA,s ...
(Date:7/10/2014)... 10, 2014   LabStyle Innovations Corp . ... announced the appointment of Professor Richard B. ... Board of Directors. Prof. Stone brings ... to LabStyle as an entrepreneur, venture capitalist public, ... governance expert. He currently serves on the board ...
(Date:7/10/2014)... -- Decision Resources Group finds that over half of ... Drug Administration,s (FDA) approval of Vifor Fresenius Medical Care ... by the FDA in November 2013 for the treatment ... dialysis. Other key findings from the report ... : , Bundling: Based ...
Breaking Medicine Technology:Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 2LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 3LabStyle Innovations Welcomes Richard B. Stone to its Board of Directors 4Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... Study) Results Demonstrate ... of VH(R) IVUS in Drug Development, SAN DIEGO, ... [ESC Booth # A2-D403], a leading manufacturer of,intravascular ultrasound ... of its VH(R) IVUS (Virtual Histology IVUS) in,GlaxoSmithKline,s IBIS-2 ...
... 1 Calabar AB, a privately,held pharmaceutical company ... EUR 350,000 equity financing from the investment company,Karolinska ... a phase II study with repeated dosing. "We ... the minor glands will lead to improved outcomes ...
Cached Medicine Technology:Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 2Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 3Volcano's VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKline's Novel Investigational Compound, Darapladib 4
(Date:7/10/2014)... 10, 2014 One week ahead of ... Safety announced today it will extend compensation benefits to ... wages for workers displaced as a result of factory ... inspections have resulted in the closure of five factories ... cases, raising immediate safety concerns. In May, the Alliance—in ...
(Date:7/10/2014)... NY (PRWEB) July 10, 2014 CBPartners, ... sciences industry, has launched a new website. The ... well as increased access to the firm’s thought pieces, ... provides an ideal platform to showcase our insights, capabilities, ... issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 A ... program that gets clients off to a great start ... can believe in, has launched a new Eating Disorders ... The new section highlights:, , Different ... Statistic Manual of Mental Disorders (DSM-IV), including anorexia nervosa, ...
(Date:7/10/2014)... A new study from Colorado School of Public ... health remains a major problem in the Navajo Nation ... among Native Americans is abysmal with more than three ... said Terrence Batliner, DDS, MBA, associate director of the ... of Public Health. "The number one problem is access ...
(Date:7/10/2014)... News) -- Most professional football players who have shoulder ... a new study finds. Shoulder instability is a ... return after surgery to fix the problem has been ... included 60 players who had shoulder stabilization surgery. Ninety ... to play, defined as playing in at least one ...
Breaking Medicine News(10 mins):Health News:Alliance for Bangladesh Worker Safety to Double Compensation for Displaced Factory Workers; Members Vote to Extend Wage Benefits from Two to up to Four Months 2Health News:CBPartners Announces New Website 2Health News:Latest A Forever Recovery Launches Eating Disorders Section on Website 2Health News:Study finds widespread oral health problems among Navajo 2Health News:Shoulder Surgery Gets NFL Players Back in the Game 2
... Lee, M.D., breast cancer researcher and assistant member ... grant from General Electric,s $100 million healthymagination Challenge ... genetic makeup to determine if they are predisposed ... GE,s healthymagination grant awarding initiative focuses on "finding ...
... Five Indiana University School of Medicine geriatricians are ... nationwide who will share in $2.5 million in career ... IU School of Medicine was one of the top-funded ... Medicine are: , Tochukwu Iloabuchi, M.D., advanced geriatrics ...
... H. Julia Hannay, the John and Rebecca Moores Professor ... 2012 Ester Farfel Award, a symbol of overall career ... faculty member. The annual award carries a cash prize ... honor recognizing the many roles that we may have ...
... Electrocardiograph (EKG) screening of young athletes can help identify those ... study. Researchers screened nearly more than 1,300 young athletes ... history, family history, a physical exam or prior EKG. Six ... cause sudden cardiac death. The study looked at how ...
... public health threats, early diagnosis of infectious diseases is ... globe where conventional medical tools like microscopes and cytometers ... to make disease screening quicker and simpler. ... or fluid samples are placed. Specific changes in the ...
... of small molecules that kill cancer cells caused by ... both cell and mouse models, demonstrate that the small ... proteins, thus killing the infected tumor cells. The ... issue of the journal Chemistry & Biology . ...
Cached Medicine News:Health News:Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks 2Health News:Awards to 5 IU School of Medicine physicians address critical need for geriatricians 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 2Health News:Neuropsychologist receives University of Houston's highest faculty honor 3Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 3Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 2Health News:Small molecular bodyguards kill HPV-infected cancer cells by protecting tumor-suppressor 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: